Can a tailored infusion schedule prevent fractures after stopping denosumab?
NCT ID NCT06767150
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 22 times
Summary
This study looks at women with postmenopausal osteoporosis who have been on denosumab for at least two years and are now stopping it. Stopping denosumab can cause a rapid bone loss and increase fracture risk. The trial compares two strategies using zoledronic acid infusions: one where the second infusion is given based on a blood test (crosslaps levels), and another where it is given at a fixed time. The goal is to see which approach better maintains bone density after one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL OSTEOPOROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amiens Hospital
RECRUITINGAmiens, France
Contact
-
Bordeaux Hospital
RECRUITINGBordeaux, France
Contact
-
Cahors Hospital
RECRUITINGCahors, France
Contact
-
Cochin Hospital
RECRUITINGParis, France
Contact
-
Dax Hospital
RECRUITINGDax, France
Contact
-
Lariboisiere Hospital
RECRUITINGParis, France
Contact
-
Le Mans Hospital
RECRUITINGLe Mans, France
Contact
-
Lille Hospital
NOT_YET_RECRUITINGLille, France
Contact
-
Limoges Hospital
RECRUITINGLimoges, France
Contact
-
Marseille Hsopital
RECRUITINGMarseille, France
Contact
-
Montpellier Hospital
RECRUITINGMontpellier, France
Contact
-
Nice Hospital
RECRUITINGNice, France
Contact
-
Orléans Hospital
RECRUITINGOrléans, France
Contact
-
Poitiers Hospital
RECRUITINGPoitiers, France
Contact
-
Rennes Hospital
RECRUITINGRennes, France
Contact
-
Saint Etienne Hospital
RECRUITINGSaint-Etienne, France
Contact
-
Toulouse Hospital
RECRUITINGToulouse, France
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zoledronic acid (ZOL)
What this could lead to
If successful, this could provide a safer way to stop denosumab without losing bone density or increasing fracture risk.
What could go wrong
This is a small, early-phase trial with only 200 participants, so results may not apply to everyone. The personalized approach may not outperform standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.